Modus Therapeutics AB has appointed John Öhd as chief medical officer to manage its portfolio which focuse on sickle cell disease. He joins Modus from Medivir AB where he was CMO and directed the company’s clinical research and development programme. Dr Öhd has also held senior positions at Shire Plc and AstraZeneca Plc. He received a PhD in experimental pathology from Lund University in Sweden.
Modus Therapeutics announced the appointment on 15 March 2018.
Copyright 2018 Evernow Publishing Ltd.